Business Monitor International


Thailand Pharmaceuticals & Healthcare Report

Published 22 January 2015

  • 117 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Thailand Pharmaceuticals & Healthcare Report

BMI View: Thailand will continue to be an attractive location to international drug makers as a result of its growing domestic pharmaceutical market with an ageing population and improving access to healthcare as well as its position as an entry point into the frontier markets of South East Asia. Japanese pharmaceutical companies such as Eisai in particular, have been attracted to the market and are looking to leverage the region's growth.

Headline Expenditure Projections

  • Pharmaceuticals: THB145.5bn (USD4.5bn) in 2014 to THB153.0bn (USD4.7bn) in 2015; +5.2% in local currency terms and +4.4% in US dollar terms.

  • Healthcare: THB504.2bn (USD15.5bn) in 2014 to THB536.7bn (USD16.4bn) in 2015; +6.45% in local currency terms and +5.6% in US dollar terms.

Risk/Reward Index

In Q2 2015, Thailand is ranked 12th out of the 19 key markets in Asia Pacific. In Q215, Thailand remains ranked broadly in the middle of the Pharmaceutical RRI table assessing the attractiveness of the 19 countries in the Asia Pacific region. This is because while Thailand remains relatively attractive to pharmaceutical investors with a growing pharmaceutical sector, its overall score is dragged down by the risks, including low levels of patent protection that is imposed to drugmakers where it scores 16.3 out of a total of 35, significantly below the regional average of 19.5.

Key Trends & Developments

  • In January 2015, health activists criticised government plans to National Health Security Office Act 2022 by charging for user services. This comes as Thailand's health permanent secretary Narong Sahametapat claims that more than 400 hospitals are experiencing financial problems and that the UC budget is depriving patients of quality care.

  • In December 2014, Pfizer (Thailand) expressed its confidence in becoming the leader of Thailand's pharmaceutical industry in terms of market share. In 2015, the company's business strategy will be to provide healthcare information to the population through...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
21
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
23
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
28
Table: OTC Medicine Sales Indicators by Category, 2006-2008
29
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Thailand 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2012-2018)
32
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Economic Activity (Thailand 2009-2018)
40
Industry Risk Reward Index
41
Asia Pacific Risk/Reward Index
41
Thailand Risk/Reward Index
47
Rewards
47
Risks
47
Market Overview
50
Industry Trends And Developments
51
Epidemiology
51
Communicable Diseases
52
Healthcare System
53
Healthcare Insurance
54
Recent Health Insurance Developments
55
Medical Tourism
57
Research And Development (R&D)
59
Biosimilars
60
Clinical Trials
61
Regulatory Development
63
Regulatory Regime
63
Regulatory Development
64
Regional Harmonisation
65
Intellectual Property Regime
66
IP Shortcomings
66
IP Developments
68
Pricing And Reimbursement
68
Table: Price Build-Up Of Medicines In Thailand
69
Competitive Landscape
71
Pharmaceutical Industry
71
Domestic Pharmaceutical Industry
72
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
73
Foreign Pharmaceutical Industry
73
Table: PReMA Members
73
Recent Pharmaceutical Industry Developments
74
Pharmaceutical Wholesale
75
Pharmaceutical Retail
77
Company Profile
79
Siam Pharmaceutical
79
Government Pharmaceutical Organisation
81
Biolab
85
Thai Meiji Pharmaceutical Company
87
Berlin Pharmaceutical Industry
89
Pfizer
91
Sanofi
94
GlaxoSmithKline
97
Merck & Co
100
Novartis
103
Demographic Forecast
106
Table: Thailand's Population By Age Group, 1990-2020 ('000)
107
Table: Thailand's Population By Age Group, 1990-2020 (% of total)
108
Table: Thailand's Key Population Ratios, 1990-2020
109
Table: Thailand's Rural And Urban Population, 1990-2020
109
Glossary
110
Methodology
112
Pharmaceutical Expenditure Forecast Model
112
Healthcare Expenditure Forecast Model
112
Notes On Methodology
113
Risk/Reward Index Methodology
114
Index Overview
115
Table: Pharmaceutical Risk/Reward Index Indicators
115
Indicator Weightings
116

The Thailand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thailand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Thailand, to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc